Dopamine D2 receptor antagonist-Pipeline Insight, 2021 | Analytical Research Cognizance

Dopamine D2 receptor antagonist-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667930
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Dopamine D2 receptor antagonists– Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dopamine D2 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Dopamine D2 receptor antagonists Understanding
Dopamine D2 receptor antagonists: Overview
DRD2 encodes the D2 subtype of the dopamine receptor that inhibits adenylyl cyclase activity. Alternative splicing of this G protein-coupled receptor results in two transcript variants encoding different isoforms. DRD2 plays a major role in the neural circuitry that mediates behavioral control, an ability that is essential for adaptive responding and is compromised in a variety of common neuropsychiatric disorders.

Function – Dopamine receptors are G protein–coupled receptors involved in the regulation of motor activity and several neurological disorders such as schizophrenia, bipolar disorder, Parkinson’s disease (PD), Alzheimer’s disease, and attention-deficit/hyperactivity disorder. Dopamine is a monoamine catecholamine neurotransmitter belonging to the 7 transmembrane G protein–coupled receptors (GPCRs), which play an important role in the regulation of not only motor functions but also non-motor functions such as motivation, cognition, emotion, and neuroendocrine secretion.

Dopamine D2 receptor antagonists- Dopamine (DA) D2 receptor antagonists have been linked to elevated levels of nicotine dependence in smokers with schizophrenia. Because activation of D2 receptors mediates motivation for nicotine, potent D2 antagonists would diminish nicotine's ability to stimulate reward processing-a mechanism that may drive compensatory increases in smoking.

Dopamine D2 receptor antagonists Emerging Drugs Chapters
This segment of the Dopamine D2 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dopamine D2 receptor antagonists Emerging Drugs
Pridopidine: Prilenia Therapeutics
Pridopidine is an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day. Pridopidine is being evaluated in Phase III stage of development for the treatment of patients with Huntington's disease.

FKF 02SC: Fabre-Kramer Pharmaceuticals
FKF 02SC is a potent dopamine D2 receptor antagonist being developed by Fabre-Kramer Pharmaceuticals. The drug is currently in Phase II stage of development for the treatment of patients with Schizophrenia.
Further product details are provided in the report……..

Dopamine D2 receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Dopamine D2 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Dopamine D2 receptor antagonists
There are approx. 10+ key companies which are developing the Dopamine D2 receptor antagonists. The companies which have their Dopamine D2 receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Prilenia Therapeutics
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Dopamine D2 receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Oral
Parenteral
Subcutaneous
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dopamine D2 receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine D2 receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine D2 receptor antagonists drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine D2 receptor antagonists R&D. The therapies under development are focused on novel approaches for Dopamine D2 receptor antagonists.

Dopamine D2 receptor antagonists Report Insights
Dopamine D2 receptor antagonists Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Dopamine D2 receptor antagonists Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing Dopamine D2 receptor antagonists drugs?
How many Dopamine D2 receptor antagonists drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for Dopamine D2 receptor antagonists?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine D2 receptor antagonists therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Dopamine D2 receptor antagonists and their status?
What are the key designations that have been granted to the emerging drugs?

Introduction
Executive Summary
Dopamine D2 receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dopamine D2 receptor antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dopamine D2 receptor antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dopamine D2 receptor antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pridopidine: Prilenia Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
FKF 02SC: Fabre-Kramer Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MRTX-1133: Mirati Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dopamine D2 receptor antagonists Key Companies
Dopamine D2 receptor antagonists Key Products
Dopamine D2 receptor antagonists- Unmet Needs
Dopamine D2 receptor antagonists- Market Drivers and Barriers
Dopamine D2 receptor antagonists- Future Perspectives and Conclusion
Dopamine D2 receptor antagonists Analyst Views
Dopamine D2 receptor antagonists Key Companies
Appendix

Table 1 Total Products for Dopamine D2 receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Dopamine D2 receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products